UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (20), p.5855-5865

2014

Volltextzugriff (PDF)

Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial

The lancet oncology, 2012-02, Vol.13 (2), p.145-153

2012

Volltextzugriff (PDF)

DNA-PKcs Expression Is a Predictor of Biochemical Recurrence After Permanent Iodine 125 Interstitial Brachytherapy for Prostate Cancer

International journal of radiation oncology, biology, physics, 2016-07, Vol.95 (3), p.965-972

2016

Volltextzugriff (PDF)

Reoxygenation during radiotherapy in intermediate-risk prostate cancer

Radiotherapy and oncology, 2019-04, Vol.133, p.16-19

2019

Volltextzugriff (PDF)

Delineation of the Prostate Bed: The "Invisible Target" Is Still an Issue?

Frontiers in oncology, 2017-05, Vol.7, p.108-108

2017

Volltextzugriff (PDF)

Definition of lymph node areas for radiotherapy of prostate cancer: A critical literature review by the French Genito-Urinary Group and the French Association of Urology (GETUG-AFU)

Cancer treatment reviews, 2015-12, Vol.41 (10), p.814-820

2015

Volltextzugriff (PDF)

70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial

International journal of radiation oncology, biology, physics, 2011-07, Vol.80 (4), p.1056-1063

2011

Volltextzugriff (PDF)

Nomograms to predict late urinary toxicity after prostate cancer radiotherapy

World journal of urology, 2014-06, Vol.32 (3), p.743-751

2014

Volltextzugriff (PDF)

DNA-PKcs Expression Predicts Response to Radiotherapy in Prostate Cancer

International journal of radiation oncology, biology, physics, 2012-12, Vol.84 (5), p.1179-1185

2012

Volltextzugriff (PDF)

Tricyclic Series of Heat Shock Protein 90 (Hsp90) Inhibitors Part I: Discovery of Tricyclic Imidazo[4,5-c]pyridines as Potent Inhibitors of the Hsp90 Molecular Chaperone

Journal of medicinal chemistry, 2011-10, Vol.54 (20), p.7206-7219

2011

Volltextzugriff (PDF)

An Antibody–Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities

Molecular cancer therapeutics, 2020-08, Vol.19 (8), p.1660-1669

2020

Volltextzugriff (PDF)

Brachytherapy versus prostatectomy in localized prostate cancer: Results of a French multicenter prospective medico-economic study

International journal of radiation oncology, biology, physics, 2007-03, Vol.67 (3), p.812-822

2007

Volltextzugriff (PDF)

T1-T2 prostate cancer: treatment by radiation therapy

Bulletin du cancer, 2007-07, Vol.94 (7 Suppl), p.F5

2007

Volltextzugriff (PDF)

Traitement à domicile par l’acide zolédronique chez des patients atteints de tumeurs solides : observance et satisfaction du patient et de l’infirmier

Bulletin du cancer, 2013-03, Vol.100 (3), p.247-257

2013

Volltextzugriff (PDF)

1359: Individual patient data analysis of salvage radiotherapy trials: RTOG 0534 and GETUG-AFU 16

Radiotherapy and oncology, 2024-05, Vol.194, p.S2426-S2427

2024

Volltextzugriff (PDF)

The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: Feasibility and acute toxicity

International journal of radiation oncology, biology, physics, 2004-11, Vol.60 (4), p.1056-1065

2004

Volltextzugriff (PDF)

Evaluation of tumor hypoxia prior to radiotherapy in intermediate-risk prostate cancer using [18]F-fluoromisonidazole PET/CT: a pilot study

Oncotarget, 2018, Vol.9 (11), p.10005-10015

2018

Volltextzugriff (PDF)

An open-label, first-in-human, dose escalation study of a novel CD3-CD123 bispecific T-cell engager administered as a single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high risk myelodysplastic syndrome

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS7076-TPS7076

2018

Volltextzugriff (PDF)

Abstract 3580: Noninvasive immuno-PET imaging of CD8+T cell behavior in tumor bearing mice models treated with SAR444245

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.3580-3580

2023

Volltextzugriff (PDF)

Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for metastatic free survival (MFS) after radical prostatectomy (RP): Update at 9 years of the GETUG-AFU 16 phase III randomized trial (NCT00423475)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.5001-5001

2019

Volltextzugriff (PDF)

Home-based zoledronic acid infusion therapy in patients with solid tumours: compliance and patient–nurse satisfaction

Supportive care in cancer, 2013-06, Vol.21 (6), p.1613-1620

2013

Volltextzugriff (PDF)

1 – 25 von 65

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(61)
Mit Volltextzugriff
(61)

Publikationsform

Artikel
(65)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(29)
Science & Technology
(29)
Humans
(24)
Oncology
(23)
Male
(17)
Aged
(13)
Middle Aged
(13)
Life Sciences
(10)
Prostate Cancer
(10)
Prostatic Neoplasms - Radiotherapy
(10)
Hematology, Oncology And Palliative Medicine
(9)
Radiology, Nuclear Medicine & Medical Imaging
(9)
Aged, 80 And Over
(8)
Female
(8)
Prostatic Neoplasms - Pathology
(8)
Adult
(6)
Animals
(6)
Biological And Medical Sciences
(6)
Brachytherapy
(6)
Mice
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial

Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial

SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression

Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial

DNA-PKcs Expression Is a Predictor of Biochemical Recurrence After Permanent Iodine 125 Interstitial Brachytherapy for Prostate Cancer

Reoxygenation during radiotherapy in intermediate-risk prostate cancer

Delineation of the Prostate Bed: The "Invisible Target" Is Still an Issue?

Definition of lymph node areas for radiotherapy of prostate cancer: A critical literature review by the French Genito-Urinary Group and the French Association of Urology (GETUG-AFU)

70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial

Nomograms to predict late urinary toxicity after prostate cancer radiotherapy

DNA-PKcs Expression Predicts Response to Radiotherapy in Prostate Cancer

Tricyclic Series of Heat Shock Protein 90 (Hsp90) Inhibitors Part I: Discovery of Tricyclic Imidazo[4,5-c]pyridines as Potent Inhibitors of the Hsp90 Molecular Chaperone

An Antibody–Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities

Correction to Tricyclic Series of Heat Shock Protein 90 (Hsp90) Inhibitors Part I: Discovery of Tricyclic Imidazo[4,5-c]pyridines as Potent Inhibitors of the Hsp90 Molecular Chaperone

Brachytherapy versus prostatectomy in localized prostate cancer: Results of a French multicenter prospective medico-economic study

T1-T2 prostate cancer: treatment by radiation therapy

Traitement à domicile par l’acide zolédronique chez des patients atteints de tumeurs solides : observance et satisfaction du patient et de l’infirmier

1359: Individual patient data analysis of salvage radiotherapy trials: RTOG 0534 and GETUG-AFU 16

The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: Feasibility and acute toxicity

Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment

Evaluation of tumor hypoxia prior to radiotherapy in intermediate-risk prostate cancer using [18]F-fluoromisonidazole PET/CT: a pilot study

An open-label, first-in-human, dose escalation study of a novel CD3-CD123 bispecific T-cell engager administered as a single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high risk myelodysplastic syndrome

Abstract 3580: Noninvasive immuno-PET imaging of CD8+T cell behavior in tumor bearing mice models treated with SAR444245

Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for metastatic free survival (MFS) after radical prostatectomy (RP): Update at 9 years of the GETUG-AFU 16 phase III randomized trial (NCT00423475)

Home-based zoledronic acid infusion therapy in patients with solid tumours: compliance and patient–nurse satisfaction

Suchergebnisse filtern